
Business UpdateNov 16, 2026, 06:24 AM
Biohaven Ltd. Presents at Jefferies Global Healthcare Conference
AI Summary
Biohaven Ltd. is presenting an investor presentation at the Jefferies Global Healthcare Conference, detailing its diverse pipeline of drug candidates across oncology, inflammation, immunology, and ion channel therapies. The presentation highlights progress in key programs such as BHV-1300 for Graves' disease, BHV-1400 for IgA nephropathy, and Opakalim for epilepsy, alongside its obesity candidate Taldefgrobep Alfa. The company emphasizes its extracellular protein degrader technology and provides updates on clinical trial progress, including the initiation of Phase 3 trials for some assets.
Key Highlights
- Biohaven Ltd. is presenting at the Jefferies Global Healthcare Conference in London.
- The presentation includes updates on various drug development programs including oncology, inflammation & immunology, and ion channel therapies.
- Key programs highlighted include BHV-1300 (Graves' disease), BHV-1400 (IgA nephropathy), and Opakalim (epilepsy).
- Taldefgrobep Alfa, a myostatin-activin pathway inhibitor for obesity, is also featured.
- The company is advancing multiple drug candidates through clinical trials, with several in Phase 3 or initiating Phase 3.
- Biohaven is leveraging its extracellular protein degrader technology for autoimmune diseases.
- The presentation details the mechanism of action and preliminary data for several drug candidates.
Price Impact
More from BHVN